Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.40 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12597357 | 0.97 | CCKAR (0.48) | CCKARPTGS2PTGS1SLC5A1PPP1CA | |
| Formic Acid SCHEMBL1765477 | 0.91 | CCKAR (0.46) | CCKARPTGS2PTGS1SLC5A1SLC16A3 | |
| Formic Acid SCHEMBL1765040 | 0.90 | CCKAR (0.46) | CCKARSLC5A1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1765026 | 0.90 | CCKAR (0.49) | CCKARPTGS2PTGS1SLC5A1PPP1CA | |
| Formic Acid SCHEMBL1765274 | 0.90 | CCKAR (0.45) | CCKARSLC5A1 | |
| Formic Acid SCHEMBL1765453 | 0.90 | CCKAR (0.45) | CCKAR | |
| Formic Acid SCHEMBL1765337 | 0.90 | CCKAR (0.45) | CCKARPTGS2PTGS1SLC5A1 | |
| SCHEMBL1765285 | 0.90 | CCKAR (0.50) | CCKARPTGS2PTGS1SLC5A1PPP1CA | |
| Formic Acid SCHEMBL1765265 | 0.89 | CCKAR (0.46) | CCKARPTGS2PTGS1SLC5A1SLC16A3 | |
| Formic Acid SCHEMBL1765088 | 0.88 | CCKAR (0.46) | CCKARPTGS2PTGS1SLC5A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399682-B2 | Substituted (pyrazolylcarbonyl)imidazolidinones and their use | AICURIS GMBH & CO. KG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | AICURIS GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124618-A1 | SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE | TPMT, PAICS, THPO | CCKAR 4827/4885PTGS2 3497/4885PTGS1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.